IZREMA Trademark

Trademark Overview

On Monday, January 7, 2019, a trademark application was filed for IZREMA with the United States Patent and Trademark Office. The USPTO has given the IZREMA trademark a serial number of 88252295. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 18, 2022. This trademark is owned by Pfizer Inc.. The IZREMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
izrema

General Information

Serial Number88252295
Word MarkIZREMA
Filing DateMonday, January 7, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 18, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 16, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 28, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, July 18, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 18, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, October 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 29, 2021SOU EXTENSION 5 GRANTED
Thursday, October 21, 2021SOU EXTENSION 5 FILED
Friday, October 29, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 21, 2021TEAS EXTENSION RECEIVED
Tuesday, September 14, 2021ASSIGNED TO EXAMINER
Saturday, May 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 29, 2021SOU EXTENSION 4 GRANTED
Thursday, April 29, 2021SOU EXTENSION 4 FILED
Thursday, April 29, 2021TEAS EXTENSION RECEIVED
Tuesday, October 20, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 16, 2020SOU EXTENSION 3 GRANTED
Friday, October 16, 2020SOU EXTENSION 3 FILED
Friday, October 16, 2020TEAS EXTENSION RECEIVED
Friday, April 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 15, 2020SOU EXTENSION 2 GRANTED
Wednesday, April 15, 2020SOU EXTENSION 2 FILED
Wednesday, April 15, 2020TEAS EXTENSION RECEIVED
Tuesday, February 4, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 4, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 4, 2019SOU EXTENSION 1 GRANTED
Wednesday, December 4, 2019SOU EXTENSION 1 FILED
Wednesday, December 4, 2019TEAS EXTENSION RECEIVED
Wednesday, November 20, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, June 11, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 16, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 16, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 8, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 5, 2019ASSIGNED TO EXAMINER
Monday, January 28, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, January 10, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

izrema preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological